Chimerix (NASDAQ:CMRX) Given “Hold” Rating at Jefferies Financial Group

Jefferies Financial Group reissued their hold rating on shares of Chimerix (NASDAQ:CMRX) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $8.50 target price on the biopharmaceutical company’s stock, down from their previous target price of $10.00.

A number of other brokerages have also commented on CMRX. Wedbush reiterated a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday. HC Wainwright reissued a “neutral” rating and issued a $8.55 price target (down from $11.00) on shares of Chimerix in a report on Wednesday.

Chimerix Stock Up 70.6 %

Shares of NASDAQ CMRX opened at $8.46 on Wednesday. The business’s 50 day moving average price is $4.04 and its 200 day moving average price is $2.17. The firm has a market cap of $760.86 million, a P/E ratio of -9.00 and a beta of 0.32. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.47.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CMRX. Bender Robert & Associates acquired a new position in shares of Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix during the 4th quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the 4th quarter worth approximately $62,000. Diadema Partners LP acquired a new position in shares of Chimerix during the 4th quarter worth approximately $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix during the 4th quarter worth approximately $130,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.